Aging Research Roundup: Proteomic Clocks, Dog Comorbidities, and Senolytic Advances
This week's newsletter covers new findings linking accelerated proteomic aging clocks to higher mortality risk, and reveals that comorbidity patterns in dogs mirror those in humans. It also discusses automated screening methods for anti-aging compounds and highlights the PGAM1-CHK1 interaction as a promising target for selectively destroying senescent cells.
Proteomic clocks—biological aging measures based on blood protein levels—showed that accelerated aging correlates with higher mortality and age-related disease risk. Meanwhile, a study of dogs revealed comorbidity patterns closely resembling human aging, suggesting shared biological mechanisms across species.
In senolytics, researchers identified the PGAM1-CHK1 interaction as a target for selectively clearing senescent cells. Automated screening platforms are also advancing, enabling faster identification of compounds that slow aging. However, affordable interventions face a major hurdle: costly, lengthy clinical trials are needed to prove efficacy, yet funding incentives remain scarce.
These findings could reshape preventive medicine by offering earlier risk assessments through proteomic clocks, potentially guiding lifestyle or drug interventions. Dog studies may accelerate veterinary and human longevity research, while senolytic advances might eventually treat age-related diseases. Yet, without affordable clinical trial pathways, even promising therapies may stall, limiting societal benefits to those who can access unproven treatments or wait years for regulatory clarity.